Study of pharmacokinetics/pharmacodynamics of levofloxacin

National Medical Journal of China

Volumn 85, Issue 27, 2005, Pages 1926-1932

  Zhang, Jing ^a   Yu, Ji Cheng ^a   Shi, Yao Guo ^a   Zhou, Le ^a   Ye, Xin Yu ^a   Zhu, De Mei ^a   Zhang, Ying Yuan ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Ofloxacin; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTIBIOTIC AGENT; LEVOFLOXACIN; METICILLIN; PENICILLIN G;

ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG URINE LEVEL; ENTEROCOCCUS; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HEMOLYTIC STREPTOCOCCUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MORAXELLACEAE INFECTION; NONHUMAN; NORMAL HUMAN; PHARMACODYNAMICS; PREDICTION; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION; VOLUNTEER;

ADULT; HUMANS; LEVOFLOXACIN; MALE; MICROBIAL SENSITIVITY TESTS;

EID: 23044505177     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Rodvold KA, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy, 2001, 21 (10 Pt 2):233S-252S.
2. Graninger W, Zeitlinger M. Cinical applications of levofloxacin for severe infections. Chemotherapy, 2004, 50 Suppl 1:16-21.
3. Chien SC, Rogge MC, Gisclon LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother, 1997, 41:2256-2260.
4. Furlanut M, Brollo L, Lugatti E, et al. Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. J Antimicrob Chemother, 2003, 51:101-106.
5. Mark WG. Comparative antimicrobial activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother, 2003, 2:503-506.
6. Zhang L, Li JT, Lu Y, et al. Pharmacokinetics of multiple intravenous instillation of levofloxacin in Chinese healthy subjects. Acta Pharmacol Sin, 2002, 23:381-384.
7. Li GH, Zhang YY, Chen N, et al. Clinical evaluation of levofloxacin sequential therapy in the treatment of 214 patients with bacterial infections. Chin J Inect Chemother, 2004, 4:65-69.
8. Zhu DM, Wang F, Wu S, et al. Surveillance of bacterial resistance in Gram-positive cocci. Chin J Infect Chemother, 2004, 4:1-5.
9. Wang H, Yu YS, Liu Y, et al. Resistance surveillance of common community respiratory pathogens isolated in China,2002-2003. Chin J Tuberc Respir Dis, 2004, 27:155-160.
10. Firsov AA, Zinner SH, Vostrov SN, et al. AUC/MIC relationships to different endpoints of the antimicrobial effect. J Antimicrob Chemother, 2002, 50:533-539.
11. Zelenitsky SA, Ariano RE, Iacovides H, et al. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. J Antimicrob Chemother, 2003, 51:905-911.
12. Xiao YH. Concept and clinical application of antibiotic pharmacokineties/pharmacodynamics. Natl Med J China, 2004, 84: 1914-1915.
13. Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Rspiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother, 2003, 47:1867-1874.
14. Cui JC, Liu YN, Wang R, et al. Mutant prevention concentration of fluoroquinolones for staphylococcus aureus. Natl Med J China, 2004, 84:1863-1866.
15. File TM Jr, Milkovich G, Tennenberg AM, et al. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia. Curr Med Res Opin, 2004, 20: 1473-1481.
16. Chow AT, Fowler C, Williams RR, et al. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob Agents Chemother, 2001, 45:2122-2125.